Description
Cinnarizin (Cinnarizinum) Tablets 25 mg. №50
Composition
Each tablet contains 25 mg of Cinnarizine.
Mechanism of Action
Cinnarizine acts as a calcium channel blocker with antihistaminic properties, contributing to its efficacy in treating vertigo and motion sickness.
Pharmacological Properties
Cinnarizine exerts its therapeutic effects by blocking calcium channels and inhibiting the effects of histamine, thereby alleviating symptoms of vertigo, Meniere’s disease, and motion sickness.
Indications for Use
- Treatment of vertigo
- Management of Meniere’s disease
- Prevention and relief of motion sickness
Contraindications
Avoid Cinnarizin tablets in patients with Parkinson’s disease, severe hypotension, or known hypersensitivity to cinnarizine.
Side Effects
Common side effects may include drowsiness. Use caution when driving or operating machinery. Adverse effects are rare but may include gastrointestinal disturbances.
Usage Instructions
Take 25 mg (1 tablet) of Cinnarizin orally two to three times daily with or after meals to minimize gastrointestinal discomfort.
Benefits Compared to Analogues
Cinnarizine offers effective relief from vertigo and motion sickness with a well-established safety profile and proven efficacy compared to other medications in its class.
Suitable Patient Groups
Cinnarizin tablets are suitable for adults, including the elderly, and are not recommended for children without medical supervision.
Storage and Shelf Life
Store Cinnarizin tablets in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use the product after the specified shelf life.
Packaging Description
Cinnarizin tablets are available in a pack containing 50 tablets of 25 mg each, ensuring an adequate supply for the prescribed dosage regimen.
Clinical Evidence and Proven Effectiveness
Clinical studies have shown that Cinnarizine significantly reduces the severity and frequency of vertigo attacks in patients with Meniere’s disease. Research published in the International Tinnitus Journal supports the efficacy of cinnarizine in improving symptoms of vertigo and tinnitus associated with Meniere’s disease, highlighting its safety and effectiveness as a treatment option.
